RxDoctor Payments Data

Mehdi Muhammad, MD

Internal Medicine · Sugar Land, TXNPI 1346325388

Payments from drug & device makers

$3,543in general payments, 2019–2025

Across 185 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$465
  • Lilly USA, LLC$365
  • Boehringer Ingelheim$356
  • Novo Nordisk$350
  • AbbVie$321
  • Amgen$265
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,543 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$81,445
Medicare patients
145
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$154,848
TradjentaLinagliptin100$106,340
JanuviaSitagliptin Phosphate43$68,645
FarxigaDapagliflozin Propanediol42$61,427
OzempicSemaglutide34$56,041
GlyxambiEmpagliflozin/Linagliptin22$36,128
EliquisApixaban25$29,975
XareltoRivaroxaban24$27,847
MyrbetriqMirabegron23$25,409
JanumetSitagliptin Phos/Metformin Hcl14$11,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,241
VascepaIcosapent Ethyl22$9,341
Gabapentin237$5,538
Diclofenac Sodium158$3,222
Atorvastatin Calcium424$3,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$356$297,316221 claims
MerckJanuvia, Janumet$93$80,52157 claims
AstraZenecaFarxiga$465$61,42742 claims
Novo NordiskOzempic$350$56,04134 claims
Johnson & JohnsonXarelto$85$27,84724 claims
Astellas Pharma US IncMyrbetriq$81$25,40923 claims
GSKTrelegy Ellipta$171$10,24116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →